Vanda Pharmaceuticals (VNDA) Expected to Announce Quarterly Earnings on Thursday

Vanda Pharmaceuticals (NASDAQ:VNDA) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of ($1.45) per share and revenue of $59.2750 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 4:30 PM ET.

Vanda Pharmaceuticals Stock Down 5.6%

Shares of Vanda Pharmaceuticals stock opened at $7.60 on Thursday. Vanda Pharmaceuticals has a 1-year low of $3.81 and a 1-year high of $9.60. The company has a market capitalization of $449.16 million, a PE ratio of -5.35 and a beta of 0.62. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.12 and a quick ratio of 3.10. The business has a 50-day moving average of $7.09 and a 200-day moving average of $5.58.

Analysts Set New Price Targets

A number of brokerages have weighed in on VNDA. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, January 21st. HC Wainwright raised their price target on shares of Vanda Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, December 17th. UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday, January 5th. Finally, Jefferies Financial Group upped their price objective on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a research note on Wednesday, December 31st. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Vanda Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $13.63.

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. lifted its holdings in shares of Vanda Pharmaceuticals by 456.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 5,328 shares during the last quarter. Quarry LP acquired a new stake in Vanda Pharmaceuticals in the third quarter worth $53,000. Cerity Partners LLC bought a new stake in Vanda Pharmaceuticals in the second quarter valued at $69,000. Boothbay Fund Management LLC acquired a new position in shares of Vanda Pharmaceuticals during the third quarter valued at $72,000. Finally, Engineers Gate Manager LP bought a new position in shares of Vanda Pharmaceuticals during the second quarter worth about $75,000. 88.14% of the stock is currently owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.